Proton Partners International and humediQ GmbH Partner to Deliver Safe Radiotherapy
Munich, Germany, October 03, 2016 --(PR.com)-- Proton Partners International has partnered with humediQ GmbH to achieve its goal of creating centres of excellence for advanced cancer treatment in the UK and beyond by providing the latest, most advanced technology in radiotherapy patient monitoring.
Proton Partners International will operate three oncology centers in the UK over the next two years. In addition to proton therapy, the centers will offer radiotherapy and chemotherapy to private patients under medical insurance, self-pay patients and NHS patients.
Proton Partners will acquire humediQ’s IDENTIFY SURFACE patient positioning and motion management system, the most modern solution on the market, for both its conventional and proton therapy systems.
Mike Moran, Chief Executive Officer of Proton Partners International, says: “We are committed to providing the highest quality of treatment at our centers and as such we are working with world class-leading partners. We are pleased to be working in partnership with humediQ, which is renowned for the innovation and excellence of its products and services.”
Christian Hieronimi, Chief Executive Officer at humediQ GmbH, says: “We are very pleased to support Proton Partners in transforming care in the UK and beyond. humediQ’s comprehensive patient positioning and monitoring solutions are designed to ensure patient safety while being treated with highly accurate forms of radiation therapy. Its ease of use will play a vital role in helping Proton Partners to achieve their goal of treating more than 2,000 patients annually.”
According to Cancer Research UK, the number of new cancer cases each year in the UK is expected to reach around 432,000 by 2030, and half of these patients should receive radiotherapy at some point in their treatment. Patient safety has to be at the forefront of any radiotherapy service and with the projected increase in patient volumes, combined with the evolution of more precise hypo-fractionated treatments, accurate patient positioning and motion management will be crucial to take full advantage of these new treatment regimes.
Stewart Pegrum, humediQ’s Vice President EMEA, adds: “Proton Partners and humediQ are committed to bring the best, safest and most innovative radiotherapy solutions to cancer patients in the UK and beyond.”
About Proton Partners International Limited
Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer program, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company.
Professor Gordon McVie, Senior Consultant at the European Institute of Oncology, which partners the Italian Hadron Centre in Pavia, has been appointed non-executive chairman and Professor Karol Sikora is chief medical adviser to the company.
The Welsh Government’s Life Sciences Investment Fund is a key investor in Proton Partners International.
For more information on Proton Partners, please visit: http://proton-int.com/
Follow us on twitter @ProtonPartners
About humediQ GmbH
humediQ is a private limited company registered in Germany with offices located in Munich (HQ), Hong Kong and Atlanta.
As radiotherapy treatment becomes more complex, identifying the right setup for each patient’s treatment in a busy clinic can be challenging. It has to be done quickly and accurately to ensure the right patient is in the right location with the right technology setup. At humediQ we are committed to giving the best possible technological support that can help you enhance treatment quality and avoid mistakes caused by stress or hectic pace in the daily routine. We want to make you, your team and your patients feel confident and reassured by ensuring the right setup for each individual treatment. From the treatment room through the entire clinic!
For more information please visit: http://humediq.com/
Proton Partners International will operate three oncology centers in the UK over the next two years. In addition to proton therapy, the centers will offer radiotherapy and chemotherapy to private patients under medical insurance, self-pay patients and NHS patients.
Proton Partners will acquire humediQ’s IDENTIFY SURFACE patient positioning and motion management system, the most modern solution on the market, for both its conventional and proton therapy systems.
Mike Moran, Chief Executive Officer of Proton Partners International, says: “We are committed to providing the highest quality of treatment at our centers and as such we are working with world class-leading partners. We are pleased to be working in partnership with humediQ, which is renowned for the innovation and excellence of its products and services.”
Christian Hieronimi, Chief Executive Officer at humediQ GmbH, says: “We are very pleased to support Proton Partners in transforming care in the UK and beyond. humediQ’s comprehensive patient positioning and monitoring solutions are designed to ensure patient safety while being treated with highly accurate forms of radiation therapy. Its ease of use will play a vital role in helping Proton Partners to achieve their goal of treating more than 2,000 patients annually.”
According to Cancer Research UK, the number of new cancer cases each year in the UK is expected to reach around 432,000 by 2030, and half of these patients should receive radiotherapy at some point in their treatment. Patient safety has to be at the forefront of any radiotherapy service and with the projected increase in patient volumes, combined with the evolution of more precise hypo-fractionated treatments, accurate patient positioning and motion management will be crucial to take full advantage of these new treatment regimes.
Stewart Pegrum, humediQ’s Vice President EMEA, adds: “Proton Partners and humediQ are committed to bring the best, safest and most innovative radiotherapy solutions to cancer patients in the UK and beyond.”
About Proton Partners International Limited
Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer program, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company.
Professor Gordon McVie, Senior Consultant at the European Institute of Oncology, which partners the Italian Hadron Centre in Pavia, has been appointed non-executive chairman and Professor Karol Sikora is chief medical adviser to the company.
The Welsh Government’s Life Sciences Investment Fund is a key investor in Proton Partners International.
For more information on Proton Partners, please visit: http://proton-int.com/
Follow us on twitter @ProtonPartners
About humediQ GmbH
humediQ is a private limited company registered in Germany with offices located in Munich (HQ), Hong Kong and Atlanta.
As radiotherapy treatment becomes more complex, identifying the right setup for each patient’s treatment in a busy clinic can be challenging. It has to be done quickly and accurately to ensure the right patient is in the right location with the right technology setup. At humediQ we are committed to giving the best possible technological support that can help you enhance treatment quality and avoid mistakes caused by stress or hectic pace in the daily routine. We want to make you, your team and your patients feel confident and reassured by ensuring the right setup for each individual treatment. From the treatment room through the entire clinic!
For more information please visit: http://humediq.com/
Contact
humediQ GmbH
Stewart Pegrum
+49 89 649 56 28 4
www.humediq.com
Stewart Pegrum
+49 89 649 56 28 4
www.humediq.com
Contact
Categories